Clinical Trials May Misrepresent True Thromboembolic Risks From Cancer Drugs

1. Variability in reporting thromboembolic events in cancer trials may misrepresent risk. 2. Standardized and mandatory reporting is required for ethical patient consent. 3. Thromboembolic events are significant non-cancer mortality causes in chemotherapy patients. 4. Prophylaxis with rivaroxaban significantly reduces event rates. 5. Early intervention can prevent many thromboembolic complications.